Endogenous hypercortisolism (Cushing syndrome) is a well-known endocrinopathy whose clinical manifestations include many metabolic disorders (obesity, hypertension, diabetes, and osteoporosis) as well as neurocognitive and neuropsychiatric consequences \[[@B1]\]. Endogenous Cushing syndrome may be the result of an ACTH-secreting pituitary (Cushing disease), nonpituitary (ectopic) tumor, or autonomous cortisol production from adrenal glands \[[@B2]\]. Most patients with Cushing syndrome present with an indolent course over several years before the clinical and biochemical diagnosis is considered and established \[[@B3]\]. It is less appreciated that Cushing syndrome may present as an endocrine emergency because of the prodigious and often rapid onset of hypercortisolism, with very serious and life-threatening metabolic, infectious, and neuropsychiatric sequela. Most of these patients have an ectopic ACTH-secreting tumor; the rapid control of severe cortisol excess is mandatory and may be life-saving \[[@B4]\].

Medical therapy for severe hypercortisolemia is challenging and options are limited. Inhibition of adrenal steroidogenesis and direct antagonism of glucocorticoid receptors have been used in patients with Cushing syndrome. The most widely used adrenostatic agents, ketoconazole and metyrapone, normalize cortisol secretion in only 50% of patients with Cushing disease \[[@B5]\]. In addition, "serious hepatotoxicity, including cases with a fatal outcome or requiring liver transplantation has occurred with the use of oral ketoconazole" \[[@B6]\], thus limiting its use in many severely ill patients, whereas metyrapone is difficult to acquire in the United States. Although mifepristone, a glucocorticoid receptor antagonist, ameliorates the signs and symptoms of cortisol excess, particularly hyperglycemia, it has not been extensively studied in critically ill patients with severe hypercortisolemia \[[@B7]\].

Etomidate, an imidazole derivative similar to ketoconazole, is an intravenous hypnotic nonbarbiturate induction agent often used for intubation. After its introduction in the 1970s, etomidate was shown to substantially and rapidly decrease cortisol secretion \[[@B8], [@B9]\]. Subsequently, it was discovered that etomidate decreases steroidogenesis by inhibiting not only side chain cleavage enzyme but also 11*β*-hydroxylase, an enzyme that catalyzes the production of cortisol from its immediate precursor, 11-deoxycortisol \[[@B10]\]. Accordingly, reports of the successful use of etomidate to rapidly control severe hypercortisolemia emerged in the late 1980s \[[@B11]\]. Since then, most reports have been isolated case studies, with \<20 total patients reported in the literature \[[@B12]\].

Here we report a standardized intravenous etomidate protocol from our institutions for the control of severe hypercortisolemia that was used in nine separate episodes (seven patients with severe Cushing syndrome, of whom two had two separate episodes of etomidate infusion). This protocol should help clinicians manage patients with severe metabolic and neuropsychiatric consequences of prodigious hypercortisolemia and serve as a bridge to more long-term medical or definitive surgical therapy.

1. Materials and Methods {#s5}
========================

This is a descriptive retrospective analysis of patients who were admitted to Froedtert Hospital in Milwaukee, Wisconsin, or NorthShore University Health System, Evanston, Illinois, and were initiated on a standardized intravenous etomidate protocol for the control of severe hypercortisolemia. The protocol was developed by the surgical intensive care clinical pharmacists in collaboration with endocrinologists and surgeons. Its development was based on the interpretation of published case reports and their understanding of pharmacokinetic and pharmacodynamic principles. At the time of therapy, this protocol was not approved by the institutions' Pharmacy, Nutrition, and Therapeutic Committees, but it existed as a newly developed departmental protocol ([Fig. 1](#F1){ref-type="fig"}). Patients were included if they received the etomidate infusion for treatment of hypercortisolism between January 1, 2012, and December 31, 2015. Patients were to be excluded if they were \<18 years of age or pregnant, although no patients were ultimately excluded for either of these reasons. This retrospective review was approved by the institutional review boards of Froedtert Hospital and the Medical College of Wisconsin and of NorthShore University Health System.
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Etomidate infusion protocol.
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In preparation for etomidate infusion, all patients were admitted to the intensive care unit, where close metabolic, hemodynamic, respiratory, and neurologic monitoring was initiated. Before treatment with etomidate, the following laboratory parameters were obtained: serum basic chemistry (sodium, potassium, chloride, urea nitrogen, creatinine, bicarbonate, calcium), cortisol, and ACTH. In addition, baseline blood pressure, heart rate, respiratory rate, and level of sedation were ascertained. Level of sedation was assessed by using the Richmond Agitation-Sedation Scale (RASS) score, with a target RASS score of 0, which correlates with a patient who is alert and calm \[[@B13], [@B14]\].

The etomidate infusion was formulated to a concentration of 1 mg/mL (etomidate 40 mg per 40 mL dextrose 5% in water). At the time of our first treatment, no intravenous solution compatibility or stability data were available for etomidate. Because of the low starting dose and resultant infusion flow rate that would be needed, it was necessary to dilute the etomidate. Given the concerns of diluting this relatively insoluble lipophilic medication, we chose to dilute the 2-mg/mL product in a 1:1 ratio with dextrose 5% in water, in EXCEL^®^ IV Containers (B. Braun Medical Inc., Bethlehem, PA). This chosen method was based on our well-documented preparation of a pharmaceutically similar agent, lorazepam for infusion. Lorazepam injection is a water-insoluble drug that is similarly solubilized with propylene glycol. To further safeguard against risk for possible precipitation, similar to lorazepam infusion administration, the etomidate infusion was given through a 0.2-micron inline filter. Given the lack of evidence for long-term stability of this solution, we assigned the prepared solution a 24-hour expiration. Following the baseline patient assessments, an optional 5-mg IV bolus of etomidate was administered over 2 to 3 minutes and a continuous infusion of etomidate was initiated at a rate of 0.02 to 0.04 mg/kg/h. During the etomidate infusion, with an abundance of caution, serum cortisol was measured at least every 6 hours, along with basic chemistry. All measurements of cortisol were performed with the Roche Elecsys® Cortisol I assay (Roche Diagnostics, Risch-Rotkreuz, Switzerland). This assay has a 4.1% cross-reactivity with 11-deoxycortisol, which increases with etomidate use. ACTH was measured by using an electrochemiluminescence immunoassay manufactured by Roche Diagnostics, Inc. (Indianapolis, IN) performed in the Cobas e or Modular system. The detectable range for this assay is 1.0 to 2000 pg/mL.

Vital signs were taken hourly, and sedation assessments were conducted every 4 hours per standard of care for patients receiving a continuous infusion sedative. On the basis of the absolute values and the rate of change in serum cortisol, the etomidate infusion was titrated in increments of 0.01 to 0.02 mg/kg/h to target a default cortisol concentration of 10 to 20 μg/dL. A goal cortisol of 10 to 20 μg/dL was chosen because it is slightly above the "normal" cortisol level and in the range expected for patients with substantial physiological stress. The goal cortisol also allows for a small increase in cortisol that can be attributed to cross-reactivity of other steroid metabolites (such as 11-deoxycortisol) that increase with etomidate use. The goal, as determined by the attending endocrinologist in collaboration with the surgeon in surgical cases, was to achieve the target cortisol concentration during a 24- to 48-hour period. Once the target cortisol concentration was achieved, the etomidate infusion was titrated to maintain serum cortisol in the desired range until long-term medical or definitive surgical treatment could be initiated.

Rate of change of the serum cortisol concentration, time to achieve serum cortisol goal, and continuous infusion rate required to achieve and maintain cortisol in the target range were of particular interest.

2. Results {#s6}
==========

A. Clinical features {#s7}
--------------------

Seven patients representing nine distinct episodes of standardized intravenous etomidate infusion for the medical treatment of severe hypercortisolemia are described. Patient clinical features are reported in [Table 1](#T1){ref-type="table"}. The diagnosis of neoplastic hypercortisolism was confirmed by elevations of serum, urine, late-night salivary cortisol, and/or ACTH measurements. Etomidate was administered to reduce preoperative cortisol before surgery in five episodes. In three of these episodes, the patient ultimately underwent surgery, and in the other two episodes, both in the same patient, therapy was discontinued in pursuit of medical management as an alternative to surgery. Etomidate was eventually discontinued in this patient as hospice care was ultimately pursued. In three episodes, patients had previously received long-term oral therapy but acutely became unable to tolerate oral therapy; therefore, etomidate was used as temporary bridge therapy. Another patient received etomidate while awaiting a special order of metyrapone to arrive to pursue long-term medical management. Baseline cortisol was elevated in all patients ([Table 1](#T1){ref-type="table"}).
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Summary of Patient Demographic Characteristics

  Episode   Diagnosis                                                            Age/Sex   Admission Diagnosis                                        Reason to Start Etomidate Therapy                                                                        Reason to Stop Etomidate Therapy                                                                                       Baseline ACTH (pg/mL)   Baseline Cortisol (µg/dL)   Lowest Cortisol (µg/dL)   Cortisol Goal (µg/dL)   Time to Goal Cortisol (h)   Cortisol Reduction Rate (µg/dL /h)   Survival to Discontinuation of Infusion
  --------- -------------------------------------------------------------------- --------- ---------------------------------------------------------- -------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------- ----------------------- --------------------------- ------------------------- ----------------------- --------------------------- ------------------------------------ -----------------------------------------
  1         Ectopic ACTH-producing tumor                                         73/F      Symptomatic Cushing syndrome, hypokalemia, hyperglycemia   Preoperative bilateral adrenalectomy                                                                     Postoperative                                                                                                          134.0                   101                         15.1                      10--20                  94                          0.92                                 Yes
  2         ACTH-secreting pituitary tumor with prior failed pituitary surgery   40/F      Hypercortisol-induced psychosis                            Preoperative bilateral adrenalectomy; inoperable tumor with extensive cavernous sinus invasion           Postoperative                                                                                                          93.5                    32                          10.6                      10--20                  26                          0.82                                 Yes
  3         Ectopic ACTH-producing tumor                                         67/F      Metastatic cancer with perforated diverticulitis           Preoperative bilateral adrenalectomy                                                                     Surgery aborted, ketoconazole and chemotherapy started                                                                 364.0                   245                         13.3                      10--20                  134                         1.73                                 Yes
  4         Ectopic ACTH-producing tumor                                         67/F      Metastatic cancer with perforated diverticulitis           Preoperative bilateral adrenalectomy                                                                     Surgery aborted in pursuit of hospice care                                                                             1002.0                  192                         53.6                      10--20                  33 (deceased)               4.20                                 No
  5         Ectopic ACTH-producing tumor                                         50/M      Symptomatic Cushing syndrome, hypokalemia, hypoxia         Await metyrapone                                                                                         Metyrapone started                                                                                                     362.0                   197                         18.2                      10--20                  36                          4.97                                 No
  6         Ectopic ACTH-producing tumor                                         19/M      Thymic carcinoid resection                                 Preoperative thymic carcinoid resection                                                                  Postoperative                                                                                                          559.4                   59                          16.5                      10--20                  29                          0.81                                 Yes
  7         ACTH-secreting pituitary tumor                                       38/F      Petrosal sinus sampling                                    No enteral access due to ileus, holding long-term ketoconazole                                           Ileus resolved, resume long-term ketoconazole                                                                          27.7                    32                          6.9                       10--20                  33                          0.78                                 Yes
  8         Metastatic adrenal carcinoma                                         49/M      Shortness of breath                                        No enteral access during intubation, holding long-term metyrapone, mitotane; ketoconazole                Enteral access achieved following extubation, resume long-term metyrapone, mitotane; ketoconazole, start pasireotide   6.3                     159                         17.0                      10--20                  131                         1.09                                 Yes
  9         Metastatic adrenal carcinoma                                         49/M      Shortness of breath                                        No enteral access during intubation, holding long-term metyrapone, mitotane; ketoconazole, pasireotide   Palliative care due to high tumor burden                                                                               6.3                     108                         27.0                      30--40                  40                          2.04                                 No

Abbreviations: F, female; M, male.

B. Dosing {#s8}
---------

All episodes were dosed per protocol, including initial dose and subsequent dose adjustments. Treatment began with an optional 5-mg intravenous bolus of etomidate. The bolus was at the discretion of the treating endocrinologist and based on desired rapidity of cortisol reduction. Starting dose was consistently 0.02 mg/kg/h, with the exception of one patient who had previously tolerated a higher infusion rate, in whom etomidate was reinitiated at 0.04 mg/kg/h. Serum cortisol levels were then measured every 6 hours. The infusion rate was maintained if the cortisol level was trending toward goal. If the cortisol level was not trending to goal, then the infusion rate was adjusted in increments of 0.01 to 0.02 mg/kg/h to achieve desired cortisol levels. The infusion rate was not up titrated more frequently than every 6 hours. A maximum allowed infusion rate was set at 0.3 mg/kg/h. This maximum infusion rate was not reached in any of the nine episodes. The maximum achieved etomidate infusion rate was identical to the infusion rate when goal cortisol levels were achieved in all episodes with a median of 0.081 mg/kg/h (range, 0.033 to 0.150 mg/kg/h). The infusion was continued for a median duration of 63.6 hours (range, 36.3 to 168.8 hours).

C. Efficacy {#s9}
-----------

In eight of the nine episodes, the target cortisol concentration was \<20 µg/dL (one episode targeted \<40 µg/dL) and was achieved in all episodes except for one where the patient entered hospice care before achieving goal. Detailed results of cortisol dynamics on therapy are shown in [Table 1](#T1){ref-type="table"}. In the episodes where etomidate therapy reached completion, median baseline cortisol was 105 µg/dL (range, 32 to 245 µg/dL). It took a median of 38 hours (range, 26 to 134 hours) to achieve a median nadir serum cortisol of 15.8 µg/dL (range, 6.9 to 27 µg/dL). The median cortisol reduction rate was 1.09 µg/dL/h (range, 0.78 to 4.97 µg/dL/h), resulting in a median reduction in cortisol of 86.8 µg/dL (range, 19.8 to 179.6 µg/dL), or a median 80% reduction (range, 67% to 95%) ([Fig. 2](#F2){ref-type="fig"}). The one patient who did not complete etomidate therapy was on a trajectory to do so before dying, representing one of the fastest rate reductions observed in this case series.

![Plot of serum cortisol vs rate of etomidate infusion in seven of the nine episodes with available data.](js.2018-00269f2){#F2}

D. Safety {#s10}
---------

All patients tolerated their etomidate infusion well. In all but one episode, mentation was measured via the RASS. At baseline, seven patients had a RASS score of 0, which remained largely unchanged throughout the infusion. One episode who was admitted with hypercortisolemia-induced psychosis had a RASS score of −1 during the infusion and improved to 0 upon termination of etomidate therapy. The one episode without documented RASS score revealed no mentation changes per physician and nursing progress notes. At no time throughout the etomidate infusion did any RASS score go \< −1 or \> 0, nor did a change in RASS score necessitate discontinuation of etomidate.

Patients did not experience any electrolyte abnormalities or substantial changes in renal function during the etomidate infusion, nor did they experience metabolic acidosis. Glucose control improved slightly overall from the beginning of therapy compared with discontinuation of therapy.

All episodes except one realized a gradual reduction in blood pressure, whereas the heart rate remained almost unchanged for all patients and did not correlate with changes in blood pressure. No patient experienced hypotension while receiving the infusion protocol.

Two episodes experienced nausea and vomiting toward the end of etomidate infusion (35 hours into a 38-hour infusion and 33 hours into a 36-hour infusion, respectively) and may be attributed to rapid reduction of cortisol levels, given a relative reduction of cortisol of 68% and 72%, respectively (cortisol of 10.3 µg/dL down from baseline level of 32.5 µg/dL and 53.6 µg/dL down from baseline level of 192.2 µg/dL). No patients required a dose adjustment as a result of adverse effects.

Cumulative median propylene glycol exposure was 90.3 g (range, 32 to 187 g) or 818 mg/kg (range, 284 to 1762 mg/kg) or 232 mg/kg/d (range, 112 to 328 mg/kg/d). No propylene glycol--related adverse effects, such as acidosis, intravascular hemolysis, altered mentation, seizure, hypoglycemia, or renal failure, were noted, although they were prospectively monitored for during the entire etomidate infusion.

3. Discussion {#s11}
=============

This report describes the implementation of a standardized continuous etomidate infusion protocol for the rapid and safe normalization of cortisol levels in patients with prodigious hypercortisolism complicated by severe life-threatening metabolic and/or neuropsychiatric manifestations. A standardized protocol for etomidate infusion was used in nine separate episodes among seven patients with severe hypercortisolemia. For all eight episodes in which therapy was completed, the protocol-driven etomidate infusion achieved a target cortisol level \< 20 µg/dL (goal \< 40 µg/dL in one episode) within a median of 36 hours ([Table 1](#T1){ref-type="table"}). Patients with ACTH-producing neoplasms (pituitary or ectopic) and non--ACTH-dependent (metastatic adrenal cortical carcinoma) hypercortisolism benefited from therapy with a median reduction in cortisol of 91.5 µg/dL throughout the duration treatment. The etomidate infusion served as a bridge to bilateral adrenalectomy in three patients and removal of a thymic neuroendocrine carcinoma in another patient. None of the patients developed any evidence of sedation or mental status changes during infusion. In addition, safety monitoring showed no substantial changes in renal function or anion gap during the etomidate infusions ([Table 2](#T2){ref-type="table"}).
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Safety Monitoring

  Variable                  Serum Sodium (mmol/L)   Serum Potassium (mmol/L)   Serum Chloride (mmol/L)   Serum HCO~3~ (mmol/L)   Serum BUN (mg/dL)   Serum Cr (mg/dL)    Serum Glucose (mg/dL)   Serum Calcium (mg/dL)   Serum Magnesium (mg/dL)   Serum Phosphorus (mg/dL)   BP (mm Hg)                HR (beats/min)   Anion Gap (mmol/L)   RASS
  ------------------------- ----------------------- -------------------------- ------------------------- ----------------------- ------------------- ------------------- ----------------------- ----------------------- ------------------------- -------------------------- ------------------------- ---------------- -------------------- -------------
  Initiation of etomidate   143 (134--146)          3.4 (2.9--4.0)             103 (98--108)             29 (22--36)             19 (10--54)         0.86 (0.59--1.89)   168 (95--239)           8.9 (7.4--9.4)          2.0 (1.9--2.3)            3.3 (2.3--4.0)             156/99 (130/60--188/97)   87 (48--112)     11 (6--16)           0 (−1 to 0)
  End of etomidate          143 (137--147)          3.6 (3.3--4.6)             105 (97--109)             27 (24--30)             12 (5--65)          0.87 (0.74--2.21)   122 (73--178)           8.7 (6.9--9.5)          1.7 (1.3--2.1)            3.1 (1.9--5.2)             116/86 (96/54--163/77)    89 (82--132)     11 (8--14)           0 (−1 to 0)

Values are expressed as the median (range). Abbreviations: BP, blood pressure; BUN, blood urea nitrogen; CR, creatinine; HR, heart rate.

Failure to promptly decrease severe hypercortisolemia may result in life-threatening cortisol--related metabolic, infectious, and neuropsychiatric complications. Etomidate is widely available and can be easily used in an intensive care unit setting. It is also the only parenterally available agent that can achieve prompt control of severe cortisol excess. Unfortunately, few oral medications can provide such rapid control of severe hypercortisolemia. Corcuff *et al.* \[[@B15]\] reported the use of a combination of metyrapone and ketoconazole for correction of severe hypercortisolism in patients with ectopic ACTH or adrenocortical carcinoma. They demonstrated a substantial improvement in clinically relevant endpoints such as blood pressure, hypokalemia, and hyperglycemia within 1 week and 1 month after starting the steroidogenic inhibitors. Ketoconazole may be associated with substantial hepatotoxicity, and its use may be precluded in some patients with severe multisystem failure associated with severe cortisol excess. Metyrapone therapy is difficult to secure in the United States without preauthorization and may take several days to become available to pharmacists and clinicians. Mifepristone, a glucocorticoid receptor antagonist, is the only US Food and Drug Administration--approved oral medication for the treatment of hyperglycemia in patients with Cushing syndrome \[[@B7]\]. Although mifepristone may be effective in the management of patients with all forms of endogenous hypercortisolism, mifepristone has not been widely used in seriously ill patients with severe hypercortisolemia. The need for preauthorization prevents quick attainment of this therapy for acutely ill patients. Sides effects also complicate its use; many patients presenting with severe hypercortisolism have substantial hypokalemia, which may be worsened by the well-appreciated potassium-lowering effects of mifepristone. In addition, glucocorticoid receptor antagonism does not reduce serum cortisol, which makes the monitoring of its effectiveness nearly impossible in the short term in patients with severe hypercortisolemia. Given these factors, mifepristone is likely not an ideal agent in the setting of acute, severe Cushing syndrome.

Although doses of etomidate need to be individualized in each clinical situation, this protocol provides clinicians with a practical algorithm to control patients with severe hypercortisolism in an intensive care unit setting with minimal morbidity. In most patients, an intravenous bolus of 5 mg of etomidate may be a good starting point, followed by a starting infusion rate of 0.02 mg/kg/h with dose titration based on frequent cortisol determinations. Our protocol recommends the measurement of cortisol at 6-hour intervals. On the basis of our safety results, combined with other reports, it is reasonable to measure serum cortisol less frequently in some patients. Two of our patients experienced some nausea and vomiting toward the end of the etomidate infusion, possibly resulting from substantial and abrupt reduction in cortisol levels. One patient had a cortisol level as low as 10.3 µg/dL. It should be recognized that total cortisol measurements by means of immunoassay may overestimate the actual cortisol level \[[@B16]\]. Because etomidate inhibits 11*β*-hydroxylase, marked increases in the precursor of cortisol synthesis, 11-deoxycortisol, are expected. Many polyclonal antibody--derived cortisol immunoassays will have substantial cross-reactivity with 11-deoxycortisol, resulting in an overestimation of the actual cortisol level. The use of more specific cortisol assays, such as a monoclonal antibody cortisol immunoassay or tandem mass spectrometry, will provide more accurate and reliable measurements of cortisol with use of an etomidate infusion.

Etomidate is highly plasma-bound and metabolized to inactive metabolites in the liver, which are then excreted in the kidneys. Consequently, elderly patients, patients with low plasma proteins, and patients with impaired liver or renal function may require reduced doses. Etomidate is a clear colorless liquid formulated in propylene glycol. Propylene glycol is used as a solubilizing agent in many topical, oral, and injectable medications \[[@B17]\]. Propylene glycol has been associated with thrombophlebitis and pain on injection \[[@B18]\]. Etomidate with propylene glycol has also been reported to cause hemolysis \[[@B19]\]. Nephrotoxicity due to proximal renal tubular injury and lactic acidosis may occur at high doses of propylene glycol \[[@B20]\]. None of our patients experienced any observed propylene glycol--related adverse effects.

Some investigators have suggested high doses of etomidate infusion (0.1 to 1.0 mg/kg/h) for complete blockade of adrenal steroid biosynthesis (target cortisol \< 5 µg/dL) and provide supplemental exogenous hydrocortisone---a \"block and replace\" strategy---as another alternative treatment strategy \[[@B12]\]. The use of a block and replace method is an option in severely ill patients but has the potential for increased side effects from higher doses of etomidate (and propylene glycol).

Several reports have been published on longer-term use of etomidate, up to 5.5 months of therapy \[[@B20], [@B21]\]. Nonetheless, it is not clear whether prolonged etomidate infusion is safe in most patients beyond 1 to 2 weeks. As such, on the basis of limited data, we currently recommend its use for no more than 7 to 10 days.

Our study has several limitations, including the small number of study participants and the lack of patients with hypercortisolism as a result of benign adrenal disease, making the generalizability of these data to that patient population unclear.

The failure of a consistent etomidate loading dose in all patients, and the wide variation in cortisol levels in the patients reported (although this wide variation in cortisol levels is certainly expected in patients with severe hypercortisolism) are also limitations. Although we could not clearly identify any advantage in achieving target cortisol levels more rapidly with a loading dose bolus injection of etomidate, we still recommend this therapy because it was well tolerated, was easily obtainable in the acute setting, and has been endorsed by others \[[@B12]\]. We strive to make dosing patient-specific by using weight-based dosing, which yielded successful outcomes in our cohort, but we acknowledge that doing so may add an opportunity for a calculation error. For institutions without a mechanism to mitigate calculation errors (*e.g.*, those without smart pump technology), it may be reasonable to avoid weight-based dosing because this approach has also demonstrated efficacy in other publications.

Additionally, none of our patients were treated with lipid a formulation of etomidate. Such a lipid formulation of etomidate (Etomidate-®Lipuro, B Braun, Melsungen, Germany) may be a therapeutic alternative to the conventional formulation of etomidate in some countries. Although it is believed to exert the same effects on cortisol metabolism, the lipid formulation may offer better tolerability with lower rates of thrombophlebitis and other propylene glycol--related toxicities because of its reduced concentration of propylene glycol. However, published reports of its use to treat hypercortisolemia are lacking, as are stability data for use as a continuous infusion.

Despite these limitations, the rarity of prodigious, life-threatening hypercortisolism, as well as the small reported number of patients with Cushing syndrome treated with etomidate, make this report and the creation of a standardized, validated protocol, with the cooperation of pharmacists and endocrinologists a valuable contribution to the management of these challenging patients.

4. Conclusion {#s12}
=============

In conclusion, our protocol-driven continuous etomidate infusion demonstrated rapid control of severe hypercortisolism secondary to neoplastic Cushing syndrome without any observed adverse side effects. This protocol should help guide clinical endocrinologists and pharmacists in the management of seriously ill patients with severe hypercortisolism as a bridge to long-term medical therapy or definitive surgical intervention.

***Disclosure Summary:*** T.B.C. is a consultant and speaker for Corcept Therapeutics. J.W.F. is a consultant for Corcept Therapeutics and Novartis. The remaining authors have nothing to disclose.
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